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Abstract. Noonan syndrome (NS) is an autosomal dominant 
disorder, characterized by short stature, multiple dysmor-
phisms and congenital heart defects. A myeloproliferative 
disorder (NS/MPD), resembling juvenile myelomonocytic 
leukemia (JMML), is occasionally diagnosed in infants with 
NS. In the present study, we performed a functional evalua-
tion of the circulating hematopoietic progenitors in a series 
of NS, NS/MPD and JMML patients. The different functional 
patterns were compared with the aim to identify a possible NS 
subgroup worthy of stringent hematological follow-up for an 
increased risk of MPD development. We studied 27 NS and 
5 JMML patients fulfilling EWOG-MDS criteria. The more 
frequent molecular defects observed in NS were mutations in 
the PTPN11 and SOS genes. The absolute count of monocytes, 
circulating CD34+ hematopoietic progenitors, their apoptotic 
rate and the number of circulating CFU-GMs cultured in the 
presence of decreasing concentrations or in the absence of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) 
were evaluated. All JMML patients showed monocytosis 
>1,000/µl. Ten out of the 27 NS patients showed monocytosis 
>1,000/µl, which included the 3 NS/MPD patients. In JMML 
patients, circulating CD34+ cells were significantly increased 
(median, 109.8/µl; range, 44-232) with a low rate of apoptosis 
(median, 2.1%; range, 0.4-12.1%), and circulating CFU-GMs 
were hyper-responsive to GM-CSF. NS/MPD patients showed 
the same flow cytometric pattern as the JMML patients (median, 
CD34+ cells/µl, 205.7; range, 58-1374; median apoptotic rate, 
1.4%; range, 0.2-2.4%) and their circulating CFU-GMs were 
hyper-responsive to GM-CSF. These functional alterations 
appeared 10 months before the typical clinical manifestations 
in 1 NS/MPD patient. In NS, the CD34+ absolute cell count 
and circulating CFU-GMs showed a normal pattern (median 
CD34+ cells/µl, 4.9; range, 1.3-17.5), whereas the CD34+ cell 
apoptotic rate was significantly decreased in comparison 
with the controls (median, 8.6%; range, 0-27.7% vs. median, 
17.6%; range, 2.8-49.6%), suggesting an increased CD34+ cell 
survival. The functional evaluation of circulating hematopoi-
etic progenitors showed specific patterns in NS and NS/MPD. 
These tests are a reliable integrative tool that, together with 
clinical data and other hematological parameters, could help 
detect NS patients with a high risk for a myeloproliferative 
evolution.
Introduction
Noonan syndrome (NS) is an autosomal dominant disorder, 
mainly characterized by proportionate short stature, facial and 
muscoloskeletal dysmorphisms and congenital heart defects 
(most commonly pulmonary valve stenosis and hypertrophic 
cardiomiopathy) with an incidence rate between 1:1,000 and 
1:2,500 live births (1). Further findings may include cryptor-
chidism, bleeding diathesis, lymphatic dysplasia and mild to 
moderate developmental delay/intellectual disability (DD/ID). 
A myeloproliferative disorder (NS/MPD) can occasionally be 
diagnosed in infants with NS. The clinical course of NS/MPD 
is usually benign with spontaneous remission. However, 
various cases with an aggressive course resembling juvenile 
myelomonocytic leukemia (JMML) have been described (2-6). 
JMML is a rare clonal myelodysplastic-myeloproliferative 
disorder typical of infancy and early childhood, characterized 
by spontaneous in vitro proliferation of bone marrow and 
peripheral blood hematopoietic progenitors in the absence 
of exogenous growth factors, due to selective hypersensi-
tivity to granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (7). Hepatosplenomegaly, lymphoadenopathy, 
anemia, thrombocytopenia, and fever, variably associated 
with symptoms of non-hematopoietic organ infiltration, are 
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common clinical findings in JMML. The fulfillment of the 
following laboratory criteria is required for JMML diagnosis: 
an absolute monocyte count >1,000/µl, <20% bone marrow 
blasts and the absence of t (9;22) or BCR/ABL rearrangement. 
Apart from such mandatory criteria, JMML patients may 
present with a high white blood cell count (>10,000/µl), imma-
ture myeloid precursors on a peripheral smear and increased 
fetal hemoglobin (HbF) for age. Monosomy 7 is quite 
frequently noted (8).
Both NS and JMML are characterized by hyperactiva-
tion of the RAS/MAPK signaling pathway. In NS, germline 
missense mutations in genes such as PTPN11, KRAS, SOS1, 
RAF1, BRAF, SHOC2, NRAS and CBL (9-19) have been 
documented. In JMML, mutually exclusive somatic mutations 
of PTPN11, KRAS, NRAS and NF1 genes can be found in 
~75% of cases. NS is associated with germline PTPN11 muta-
tions in ~50% of the patients, while somatic PTPN11 mutations 
are found in 35% of children with JMML. This gene encodes 
for the ubiquitously expressed non-receptor protein tyrosine 
phosphatase (PTP) SHP-2, which is implicated in a variety of 
intracellular signaling cascades mediated by growth factors, 
cytokines, hormones and cell adhesion molecules (20,21). 
SHP-2 is also involved in several developmental processes, in 
particular semi-lunar valvulogenesis (22) and hematopoietic 
cell differentiation (23,24). PTPN11 mutations favor either 
the basal activity or the response to inducing events of the 
catalytically active conformation of SHP-2, resulting in gain 
of function (11). The PTPN11 mutational spectrum has been 
shown to be different in JMML, NS/MPD and NS without any 
hematological abnormalities (5).
We previously demonstrated that flow cytometric evalua-
tion of the absolute count of peripheral blood (PB) CD34+ cells 
and the apoptotic rate is a simple and repeatable technique, 
useful for early detection of clonal evolution in acquired 
aplastic anemia. In children with de novo or secondary refrac-
tory anemia with blast excess (RAEB) we observed a typical 
pattern of a high PB CD34+ count associated with a low apop-
totic rate, sometimes evident months before the appearance of 
the complete clinical image (25).
In the present study, we performed a functional evaluation 
of the circulating hematopoietic progenitors in a series of NS 
patients. Clonogenic tests in the absence or in the presence 
of increasing concentrations of GM-CSF and three-color flow 
cytometric analysis for CD45, CD34, and Annexin V were 
performed using the PB of 27 patients with NS and 5 patients 
with JMML. The different functional patterns were compared 
to identify a possible NS subgroup worthy of stringent hema-
tological follow-up for an increased risk of MPD development.
Materials and methods
Patients. Included in the present study were 27 patients 
admitted to Department of Pediatrics with a clinical diag-
nosis of NS (independently of their mutational status and the 
presence of hematological anomalies). Three patients had a 
myeloproliferative disorder (NS/MPD), with monocytosis, 
atypical monocytoid cells, myelodysplastic features and 
granulocyte precursors in PB, thrombocytopenia and hepato-
splenomegaly (2-6). Five patients with a diagnosis of JMML, 
fulfilling the EWOG-MDS criteria (8) were also studied. PB 
samples were collected in EDTA at diagnosis. Further blood 
samples were collected and analyzed in NS patients when 
hematological anomalies (e.g. anemia, thrombocytopenia, 
leukocytosis, splenomegaly, lymphadenopathy) and/or altera-
tions of the functional pattern of circulating hematopoietic 
progenitors were observed. NS/MPD and JMML patients 
were evaluated at various stages during follow-up and treat-
ment. Ethics committee approval and informed consent of the 
parents of the patients were obtained.
Genomic mutational analysis. Genomic DNA was isolated 
from 200 µl of PB by the QIAamp DNA Blood Mini kit 
(Qiagen, Germantown, MD, USA). A molecular analysis of 
PTPN11, KRAS, SOS1, RAF1, BRAF, SHOC2, NRAS and 
CBL was performed as previously described (11-20).
Absolute count of CD34+ cells and the apoptotic index. Flow 
cytometric analysis was performed within 2 h after venipunc-
ture. The absolute count of CD34+ cells and the apoptotic rate 
were evaluated by a three-color fluorescence for CD45, CD34 
and Annexin V as follows. A total of 5x105 nucleated cells 
were incubated for 20 min at 4˚C with anti-CD34 PE (8G12; 
Becton-Dickinson, San José, CA, USA) and anti-CD45 PerCP 
(2D1; BD Biosciences, Franklin Lakes, NJ, USA). After incu-
bation and red cell lysis by ammonium chloride, the samples 
were washed in cold phosphate-buffered saline (PBS) and 
incubated with Annexin V-fluorescein isothiocyanate (FITC) 
(Apoptosis Detection kit; R&D Systems, Minneapolis, MN, 
USA), according to the manufacturer's instructions. The cells 
were then analyzed in a Coulter Epics XL2 (IL, Bedford, MA, 
USA) cytometer equipped with an argon laser. CD34+ cells 
were identified by a sequential gating strategy according to the 
ISHAGE protocol (26). Absolute CD34 counts were assessed 
by a two-platform method with a Sysmex K4500 counter 
(Sysmex Corporation, Kobe, Japan). At least 100 CD34+ cells 
were evaluated in each experiment.
Cell cultures. Low-density mononuclear cells (2x105) obtained 
from the patient PB by density centrifugation over Ficoll-
Hypaque gradient were plated in multi well plates in 250 µl 
Iscove's modified Dulbecco's medium (IMDM) containing 
30% fetal calf serum (FCS) (both from Sigma-Aldrich, St. 
Louis, MO, USA), 0.3% noble agar and 100 U/ml rhIL-3 and 
decreasing concentrations (20, 10, 5, 1, 0.1 ng/ml) of rhGM-
CSF (both from Invitrogen Life Technologies, Carlsbad, CA, 
USA). After 14 days, single aggregates of >40 cells were 
scored as CFU-GMs. GM-CFU assay was also performed 
without GM-CSF stimulation. GM-CFU assay in the same 
culture conditions was also performed in 21 pediatric controls 
(median age, 9.0; range, 1-18 years).
Statistical analysis. The patients were divided into 3 groups: 
NS, NS/MPD and JMML. Historical controls (n=68) from our 
laboratory were utilized for the absolute count of CD34+ in PB 
and the apoptotic rate (25).
For the absolute count of CD34+ cells and apoptotic rate, 
the values for each patient were compared with the mean 
control value adjusted for age, as previously published (25).
The cell culture data and the absolute count of CD34+ 
cells and the apoptotic rate results were analyzed using the 
ONCOLOGY REPORTS  30:  553-559,  2013 555
non-parametric Kruskal-Wallis test. Pairwise comparisons for 
the disease groups were performed for each of the GM-CSF 
concentration utilized in the cell cultures, as well as for the 
4 variables analyzed in the test (absolute CD34+, percentage 
of CD34+/Annexin V+, absolute CD34+ to the mean age group 
value ratio, percentage of CD34+/Annexin V+ to the mean age 
group value ratio). Fisher's exact probability test was utilized 
for correlations between the groups.
Results
Mutational spectrum of the patients. The mutational spectrum 
of our series of NS, NS/MPD and JMML patients is shown in 
Table I.
Monocyte counts. All JMML patients showed mono-
cytosis >1,000/µl. Ten out of the 27 NS patients showed 
Table I. Mutational spectrum, WBC, PLT and monocyte counts, CD34+ absolute count and apoptotic rate, CFU-GM from peri-
pheral blood in a series of NS, NS/MPD and JMML patients.
Patient Mutated Mutation Hypersensitivity Unstimulated Annexin V+/CD34+ CD34 WBC Monocytes PLT
 gene  to GM-CSF colony (%) (/µl) (103/µl) (103/µl) (103/µl)
    growth
NS1 PTPN11 Gln79Arg No No 8.5 L 3.6 N 11.9 0.740 284
NS2 PTPN11 Asn58His No No 26.1 H 7 N 11.6 0.400 262
NS3 PTPN11 Tyr63Cys No No 16.1 N 2.5 L 8.3 0.300 428
NS4 PTPN11 Gly503Arg No No 2.56 L 3.42 L 17.1 1.720 331
NS5 PTPN11 Gly503Glu No No 7.6 L 3.6 N 7.3 0.900 249
NS6 PTPN11 Asn308Ser No No 12 L 6.2 H 10.3 0.690 297
NS7 PTPN11 Leu261His No No 10 L 2.9 N 5.8 0.470 416
NS8 PTPN11 Leu261His No No 0 L 4.8 N 12.0 0.770 376
NS9 PTPN11 Leu261His No No 10 L 17.52 H 7.3 0.600 277
NS10 PTPN11 Phe285Ile No No 7.9 L 3.8 N 7.7 0.410 218
NS11 PTPN11 Glu76Asp Yes Yes 1.0 L 12 H 12.0 1.140 300
NS12 PTPN11 Glu139Asp No No 17.8 L 2.2 L 7.3 0.510 198
NS13 PTPN11 Asp61Asn Yes No 4.1 L 13.8 H 15.3 0.840 212
NS14 SOS Ile252Thr No No 27.7 H 2.6 L 6.4 0.450 259
NS15 SOS Thr266Lys No No 8.8 L 16.2 H 12.5 0.620 291
NS16 SOS Arg552Gly No No 18.2 L 1.3 L 4.3 0.340 259
NS17 SOS Glu433Lys No No 0 L 7.75 N 15.5 1.420 422
NS18 RAF1 Ser257Leu No No 8 L 2.5 L 6.4 0.540 253
NS19 SOS Met269Thr Yes No 4.4 L 5.2 N 8.7 1.100 182
NS20 n.d. n.d. No No 11.2  N 4.5 L 12.2 1.110 184
NS21 KRAS Gln22Arg No No 15.7 L 5.6 N 9.44 0.630 551
NS22 BRAF Leu597Val No No 0.09 L 7.1 H 7.9 1.600 397
NS23 RAF1 Pro261Ser No No 25 H 5 N 12.6 1.450 384
NS24 SHOC2 Ser2Gly No No 6.8 L 8.5 N 17.0 0.700 482
NS/MPD1 PTPN11 Phe285Ser Yes Yes 2.4 L 58.0 H 14.5 2.500 399
NS/MPD2 PTPN11 Asp61Asn Yes Yes 0.2 L 1,374 H 43.5 5.520   54
NS/MPD3 PTPN11 Asp61Asn Yes No 1.6 L 205.7 H 20.2 2.550 167
JMML1 n.d. n.d. Yes Yes 2.1 L 193.6 H 9.3 1.900   55
JMML2 PTPN11 Glu76Gly Yes Yes 12.1 N 44 H 8.8 1.380   31
JMML3 PTPN11 Gly503Val Yes No 7.2 L 49.6 H 3.1 1.070   45
JMML4 NF1 n.d. Yes Yes 0.4 L 109.8 H 11.2 1.430   15
JMML5 n.m. n.d. Yes Yes 0.4 L 232 H 36.2 7.610   71
NS, Noonan syndrome patients (n=24); NS/MPD, Noonan syndrome patients with myeloproliferative evolution (n=3); JMML, juvenile myelo-
monocytic leukemia patients (n=5). For ‘% AnnexinV+/CD34+’ and ‘CD34+/µl’ categories: ‘L’ (low), indicated samples in which the values of 
Annexin V expression on CD34+ cells or the CD34+ absolute count were lower than the average -2 SD, compared to the reference values for 
the same age groups (reviewed in ref. 25); ‘N’ (normal) indicated samples in which the value was included in the average values ± 1 SD; ‘H’ 
(high) indicated samples in which the value was higher than the average +2 SD. Patient NS/MPD3 developed GM-CSF hypersensitivity during 
follow-up (Table IV). WBC, white blood count; PLT, platelets. n.d., not determined; n.m., no mutation.
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monocytosis >1,000/µl, which included the 3 NS/MPD 
patients (Tables I and II).
Platelet counts. All JMML patients showed thrombocy-
topenia as well as 1 out of the 3 NS/MPD patients. In the 
other NS patients, the platelet counts were in the range 
of normality, without a correlation with monocyte counts 
(R=0.016) (Table I).
Absolute CD34+ cell count and apoptotic rate. The PB absolute 
CD34+ cell counts and apoptotic rates in the different groups 
of patients are shown in Tables I and II. In JMML and NS/
MPD patients, we observed high levels of circulating CD34+ 
cells with a low apoptotic rate. In NS patients, CD34+ cell 
counts were normal, whereas their apoptotic rate was signifi-
cantly lower than that in the controls (p<0.01). Concerning the 
absolute CD34+cell count, statistically significant differences 
were noted among the NS and JMML (p=0.001), NS and NS/
MPD (p<0.05), controls and JMML (p<0.01), and controls 
and NS/MPD patients (p<0.05). In contrast, no differences 
in the absolute CD34+ cell count were observed between the 
controls and NS or between the NS/MPD and JMML patients. 
Normalizing the absolute CD34+cell count for age (absolute 
CD34+ to mean age group value ratio), the results from the 
pairwise comparison did not change.
A pairwise comparison of the Annexin V+ percentage 
showed a statistically significant decrease  in  the apoptotic 
rate in each disease group when compared with the controls: 
NS (p<0.01), NS/MPD (p<0.05), JMML(p<0.01); whereas no 
significant difference was observed between NS/MPD and 
JMML, JMML and NS, and NS/MPD and NS patients. When 
the percentage of Annexin V+ cells was normalized for age 
(percentage of Annexin V+/CD34+ cells to mean age group 
value ratio), the results for the pairwise comparison did not 
change.
Cell cultures. In the JMML patients, the clonogenic assays 
from PB showed hypersensitivity to GM-CSF and spontaneous 
CFU-GM growth (except in one patient previously treated with 
chemotherapy at another center who did not show spontaneous 
CFU-GM growth) (Table I). In 3 out of 3 NS/MPD patients we 
observed hypersensitivity to GM-CSF (in patient NS/MPD3 
during the follow-up) and in 2 out of 3 spontaneous CFU-GM 
growth was noted. In 2 NS patients (NS13 and NS19) we 
observed hypersensitivity to GM-CSF, and no spontaneous 
CFU-GM growth. One NS patient (NS11) showed hypersen-
sitivity to GM-CSF and spontaneous CFU-GM growth. This 
patient had a favorable clinical outcome, and the clonogenic 
assays performed 6 months later showed normal results.
We observed a significant difference in the distribution 
and in the median values of CFU-GM among the 3 groups 
(JMML, NS, NS/MPD) (Table II). Table III (pairwise 
comparisons of GM-CSF-stimulated clonogenic assays) 
showed that at different GM-CSF concentrations, JMML 
patients were significantly more responsive to GM-CSF than 
both the controls and NS patients. Concerning unstimulated 
cultures, a significant growth advantage was observed also in 
NS/MPD when compared with the controls and NS patients 
(Table III). Specifically, clonogenic assays without GM-CSF 
were able to distinguish between NS and NS/MPD patients.
Fisher's exact probability test showed a significant correlation 
between the groups in the unstimulated colony growth tests 
(0% in controls, 4.2% in NS, 80% in JMML, 66.7% in NS/
MPD, p<0.001).
Follow-up of NS and NS/MPD patients. Six NS patients 
showed isolated monocytosis >1,000/µl, 2 NS patients showed 
isolated hyper-responses to GM-CSF, 5 NS patients showed 
an isolated increase in circulating CD34+ cells. In all of these 
patients a 12-month follow-up showed no alterations in clinical 
findings. Patients NS11 and NS/MPD1 showed monocytosis 
>1,000/µl, a hyper-response to GM-CSF, CFU-GM growth 
without GM-CSF stimulation, high circulating CD34+ counts 
with a low apoptotic rate. In these 2 NS patients a clinical and 
laboratory follow-up was performed. Patient NS11 carrying 
the Glu76Asp PTPN11 mutation, was phenotypically char-
Table II. Circulating monocytes, peripheral blood CD34+ cells, their apoptotic rate and CFU-GMs in a series of NS, NS/MPD 
and JMML patients.
Clinical parameters Controls NS NS/MPD JMML
Monocytes (/µl) 600 (200-900) 695 (300-1,720) 2,550 (2,500-5,520) 1,600 (1,070-7,600)
CD34+ (/µl) 5.2 (1.8-23.1) 4.9 (1.3-17.5) 205.7 (58-1,374) 109.8 (44-232)
Annexin V+/CD34+ (%) 17.6 (2.8-49.6) 8.6 (0.0-27.7) 1.4 (0.2-2.4) 2.1 (0.4-12.1)
GM-CSF (20 ng/ml) 9 (0-26) 4 (0-34) 36 (0-84) 46 (18-258)
GM-CSF (10 ng/ml) 5 (0-18) 2 (0-30) 38 (0-76) 40 (10-244)
GM-CSF (5 ng/ml) 3 (0-18) 1 (0-24) 38 (0-50) 42 (6-262)
GM-CSF (1 ng/ml) 1 (0-16) 1 (0-23) 34 (0-62) 32 (6-264)
GM-CSF (0.1 ng/ml) 0 (0-14) 0 (0-8) 26 (0-36) 30 (2-240)
Unstimulated 0 (0-0) 0 (0-4) 4 (0-32) 18 (0-84)
NS, Noonan syndrome patients (n=24); NS/MPD, Noonan syndrome patients with myeloproliferative evolution (n=3); JMML, myelomono-
cytic leukemia patients (n=5). CFU-GMs from 2x105 circulating mononuclear cells were cultured in the presence of decreasing GM-CSF 
concentrations and without GM-CSF (unstimulated). Data are provided as mean value (range).
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acterized by polyhydramnios in the prenatal history, typical 
facial dysmorphisms, pulmonic stenosis, bilateral cryptor-
chidism and normal neuropsychomotor development. His 
clinical follow-up in the following months was normal, and a 
laboratory hematologic evaluation performed 12 months later 
showed normal response to GM-CSF, no spontaneous colony 
growth and normal CD34+ cell and monocyte counts.
Patient NS/MPD1 was first evaluated at the age of 2 months 
while she was in the cardiac surgery unit due to obstructive 
hypertrophic cardiomyopathy. A clinical diagnosis of NS was 
confirmed by the molecular analysis of the PTPN11 gene, 
that revealed the Phe285Ser mutation. A preliminary hema-
tological evaluation evidenced only mild hepatomegaly and 
monocytosis. Clonogenic assays and flow cytometry showed 
hypersensitivity to GM-CSF, spontaneous CFU-GM growth, 
increased circulating CD34+ cells with a low apoptotic rate. 
At the age of 12 months, the patient showed splenomegaly, 
thrombocytopenia and monocytosis, with the presence in the 
peripheral blood smear of 10% of atypical monocytoid cells, 
moderate myelodysplastic features and granulocyte precur-
sors. Bone marrow aspirate showed mild myelodysplasia and 
the presence of 15% of atypical monocytoid elements. A poly-
merase chain reaction (PCR) for bcr/abl rearrangement was 
negative. The HUMARA assay performed on peripheral blood 
populations was normal, excluding a frank JMML evolution 
and suggesting a polyclonal myeloproliferative disorder, 
described in NS (2). Hence, a diagnosis of NS/MPD was 
made. Thrombocytopenia and splenomegaly persisted over 
the following months, and the clinical course worsened, with a 
progressive development of lymphatic dysplasia with thoracic 
duct ectasia, progressive severe respiratory insufficiency, 
pleural effusion and exitus at the age of 20 months for acute 
cardiopulmonary failure.
Patients NS/MPD2 and NS/MPD3 were diagnosed in the 
first month of life presenting a myeloproliferative disorder. 
Table IV shows the clinical and laboratory follow-up of the 
NS/MPD patients, and Fig. 1 shows a detailed follow-up of 
patient NS/MPD1.
Table III. Pairwise comparisons of the GM-CSF-stimulated clonogenic assay in the disease groups.
Pair GM-CSF GM-CSF GM-CSF GM-CSF GM-CSF Unstimulated
 (20 ng/ml) (10 ng/ml0 (5 ng/ml) (1 ng/ml) (0.1 ng/ml)
Controls-NS 0.248 1.000 1.000 1.000 1.000 1.000
Controls-NS/MPD 1.000 1.000 1.000 1.000 0.460 0.010
Controls-JMML 0.079 0.038 0.022 0.010 0.007 0.000
NS-JMML 0.001 0.002 0.004 0.004 0.003 0.000
NS-NS/MPD 0.671 0.808 0.903 0.786 0.674 0.016
NS/MPD-JMML 1.000 1.000 1.000 1.000 1.000 1.000
NS, Noonan syndrome patients, (n=24); NS/MPD, Noonan syndrome patients with myeloproliferative evolution, (n=3); JMML, myelomono-
cytic leukemia patients, (n=5). Bold print indicates statistically significant p-values (p<0.05; Kruskal-Wallis test). CFU-GM from circulating 
mononuclear cells cultured in the presence of decreasing GM-CSF concentrations or without GM-CSF (unstimulated).
Table IV. Functional follow-up of 3 NS/MPD patients with myeloproliferative evolution.
 NS/MPD1 NS/MPD2 NS/MPD3
 ------------------------------------------- ------------------------------------------ -------------------------------------------
Parameters T0 T1 T0 T1 T0 T1
Age at T0 2 months  10 days  1 month
WBC (/µl) 14,500 8,200 43,500 8,480 20,200 16,000
Monocytes (/µl) 2,500 1,400 5,520 620 2,550 1,280
CD34+ (/µl) 58 150 1,374 13 205 45
Annexin V+ (%) 2.4 7.5 0.2 0.8 1.6 3.0
Hyper-response to GM-CSF +++ ++ +++ No No +++
Spontaneous CFU growth ++ ++ + No No No
Circulating dysplastic monocytes No +++ ++  No + No
with myeloid dysplasia
Hepatosplenomegaly No ++ No No ++ No
Thrombocytopenia No +++ ++ No No No
NS/MPD, Noonan syndrome patients with myeloproliferative evolution. T0, first observation; T1, observation at 12 months.
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Discussion
Genetic diseases associated with a high tumor risk are models 
for the study of carcinogenesis. A close correlation is often 
observed between such genetic conditions and specific acquired 
neoplastic diseases. NS and JMML were shown to be strictly 
correlated to each other. Indeed, the same signal transduction 
pathway (RAS/MAPK) is hyperactivated both in NS and in 
JMML, with an involvement of the same genes. Moreover, NS 
patients presented an increased risk of developing JMML or, 
more frequently, a transient myeloproliferative disorder asso-
ciated with Noonan syndrome (NS/MPD).
Strictly correlated to the hyperactivation of the RAS/MAPK 
pathway is the hypersensitivity to GM-CSF observed in 
JMML (7).
In the present study, we conducted a molecular study of a 
cohort of NS and JMML patients with a functional evaluation 
of their circulating hematopoietic progenitors, and correlated 
the results with the clinical-hematological course. In particular, 
our aim was to evaluate the circulating CD34+ cell count and 
apoptotic rate and to relate such findings with in vitro colony 
growth (in the absence and with increasing concentrations of 
GM-CSF), hematological features and the clinical history of 
each patient. The analyses were performed on PB, even though 
the biological variability of hematopoietic progenitor counts 
and clonogenic assays in PB is higher than in bone marrow. 
A bone marrow aspirate would have been unethical in NS 
patients without any sign of a hematological disease.
Even though a constitutional GM-CSF hypersensitivity has 
been suggested in NS (6,27), we observed hypersensitivity to 
GM-CSF in only 6 of the 27 NS patients. One of them developed 
a myeloproliferative disorder 12 months later (NS/MPD1) and 
2 patients (NS/MPD2 and NS/MPD3) had a transient myelo-
proliferative syndrome at the time of the study. In patient NS/
MPD3, a hyper-response to GM-CSF was observed during the 
follow-up, but not at diagnosis. The other 3 NS patients with 
GM-CSF hypersensitivity had normal hematological profiles. 
These data suggest that the response to GM-CSF is variable in 
NS patients.
PTPN11 mutations in JMML affect amino acids 
differently from those involved in NS (5,28,29). Somatic 
JMML-associated mutations are predicted to result in a 
stronger SHP-2 gain of function than germ-line mutations 
described in NS, and the leukemic transformation in NS seems 
related to cooperating molecular lesions (5). In our NS series, 
one patient (NS5) carried the Gly503Glu PTPN11 mutation, 
also described in JMML. Interestingly, this patient showed 
a normal hematological profile without hypersensitivity  to 
GM-CSF, but his mother, who presented with a short stature 
and typical facial appearance, as revealed by anamnestic data 
and family photographs, died due to non-Hodgkin lymphoma.
In a previous study, we observed in normal subjects a 
progressive decrease in circulating CD34+ cells and a progres-
sive increase in their apoptotic rate from the first months of 
life to adult age (25). An increase in circulating CD34+ cells 
has been described in myelofibrosis with myeloid metaplasia 
in adults (30) and in RAEB in adults (31) and in children, 
associated with a low apoptotic rate (25). Here, we observed 
a similar behavior in the JMML and in the NS/MPD patients. 
PB CD34+ cell counts in the majority of our NS patients were 
normal, but the apoptotic CD34+ cell rate was significantly 
lower than that in the controls, as in JMML and NS/MPD. 
Previous studies have pointed to an increased proliferative 
activity of hematopoietic progenitors in NS. Our results allow 
us to identify NS as a disease with a lower-than-normal apop-
totic activity of circulating hematopoietic progenitors. This 
increase in the survival of hematopoietic progenitors appears 
to be a hallmark of NS patients.
Two out of 3 NS/MPD patients shared the same functional 
pattern of JMML, characterized by high circulating CD34+ 
cell counts with a very low apoptotic rate, hypersensitivity to 
GM-CSF and spontaneous CFU-GM growth.
Figure 1. Detailed functional follow-up of patient NS/MPD1. (A) Peripheral blood absolute CD34+ cell counts (CD34/µl) and apoptotic rate (% Annexin V+) 
and absolute monocyte counts (monocytes/µl) are shown. (B) Numbers of peripheral blood CFU-GMs cultured with decreasing concentrations of GM-CSF or 
without GM-CSF stimulation (unstimulated) are shown.
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The present data represent the complex hematopoietic 
functional profile of a series of NS patients and suggest that 
the evaluation of the absolute CD34+ count and the apoptotic 
rate as well as CFU-GM assay performed on PB could be a 
non-invasive and repeatable method that can facilitate the 
identification of NS patients with a higher risk of myelopro-
liferative evolution for whom an intensified hematological 
follow-up program is justified.
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